An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: Support for a proposal to modify current regulatory guidelines

Toxicologic Pathology

Volumn 39, Issue 4, 2011, Pages 716-744

  Sistare, Frank D ^a   Morton, Daniel ^b   Alden, Carl ^c   Christensen, Joel ^a   Keller, Douglas ^d   Jonghe, Sandra De ^e   Storer, Richard D ^a   Reddy, M Vijayaraj ^a   Kraynak, Andrew ^a   Trela, Bruce ^f   Bienvenu, Jean Guy ^g   Bjurström, Sivert ^h,o   Bosmans, Vanessa ^e   Brewster, David ^i,o   Colman, Karyn ^j   Dominick, Mark ^k   Evans, John ^h,o   Hailey, James R ^l   Kinter, Lewis ^h,o   Liu, Matt ^a   Mahrt, Charles ^m   Marien, Dirk ^e   Myer, James ^l   Perry, Richard ^b   Potenta, Daniel ^j   Roth, Arthur ^b   Sherratt, Philip ^a   Singer, Thomas ^i,o   Slim, Rabih ^i,o   Soper, Keith ^a   Fransson Steen, Ronny ^h,o   Stoltz, James ⁿ   Turner, Oliver ^j   Turnquist, Susan ^b   Van Heerden, Marjolein ^e   Woicke, Jochen ^k   Degeorge, Joseph J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c Millenium   (United States)

^d Global Health Outcomes and Market Access   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f ABBOTT LABORATORIES   (United States)

^g LAB Research Inc   (Canada)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k BRISTOL MYERS SQUIBB   (United States)

^l GLAXOSMITHKLINE   (United States)

^m ELI LILLY AND COMPANY   (United States)

ⁿ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^o NONE

more..

Author keywords

carcinogenicity prediction criteria; carcinogenicity testing; genetic toxicology testing; hormonal perturbation; pharmaceutical database; preclinical research and development; rat neoplasia; regulatory guidelines

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGEN TESTING; DATA BASE; ENDOCRINE DISEASE; GENOTOXICITY; HISTOPATHOLOGY; HORMONAL PERTURBATION; NEOPLASM; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RISK FACTOR; SENSITIVITY ANALYSIS;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DATABASES, FACTUAL; DECISION TREES; DISEASE MODELS, ANIMAL; EVALUATION STUDIES AS TOPIC; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, TRANSGENIC; MUTAGENICITY TESTS; NEOPLASMS; RATS; RATS, INBRED F344; RISK FACTORS; STATISTICS AS TOPIC; TOXICITY TESTS, CHRONIC;

MUS MUSCULUS; RATTUS;

EID: 79959429790     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311406935     Document Type: Article

References (76)

1. Alden C. L., Lynn A., Bourdeau A., Morton D., Sistare F. D., Kadambi V. J., Silverman L. A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk. Vet Pathol. 2011 ;:
2. Alison R. H., Capen C. C., Prentice D. E. Neoplastic lesions of questionable significance to humans. Toxicol Pathol. 1994 ; 22: 179-86 (Pubitemid 24230961)
3. Allen D. G., Pearse G., Haseman J. K., Maronpot R. R. Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol. 2004 ; 32: 393-401 (Pubitemid 38998931)
4. Apperley G. H., Brittain R. T., Coleman R. A., Kennedy I., Levy G. P. Characterization of the -adrenoceptors in the mesovarium of the rat. Br J Pharmacol. 1978 ; 63: 345-98
5. Boffetta P., Hashibe M. Alcohol and cancer. Lancet Oncol. 2006 ; 7: 149-56 (Pubitemid 43159501)
6. Bregman C. L., Adler R. R., Morton D. G., Regan K. S., Yano B. L. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: A proposal of the Society of Toxicologic Pathology (STP). Toxicol Pathol. 2003 ; 31: 252-53 (Pubitemid 36374016)
7. Bugelski P. J., Volk A., Walker M. R., Krayer J. H., Martin P., Descotes J. Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol. 2010 ; 29: 435-66
8. Capen C. C. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol. 1997 ; 25: 39-48 (Pubitemid 27100557)
9. Capen C. C. In Endocrine and Hormonal Toxicology. Harvey P. W. Rush K. C. Cockburn A., ed. New York: John Wiley & Sons ; 1999: 42-47.
10. Capen C. C. Mechanisms of hormone-mediated carcinogenesis of the ovary. Toxicol Pathol. 2004 ; 32 (Suppl. 2). 1-5 (Pubitemid 38993908)
11. Cohen S. M. Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol Sci. 2004 ; 80: 225-29 (Pubitemid 39136376)
12. Cohen S. M. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: The two-year bioassay is no longer necessary. Toxicol Pathol. 2010 ; 38: 487-501
13. Cohen S. M., Purtilo D. T., Ellwein L. B. Ideas in pathology. Pivotal role of increased cell proliferation in human carcinogenesis. Mod Pathol. 1991 ; 4: 371-82
14. Contrera J. F., Jacobs A. C., DeGeorge J. J. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul Toxicol Pharmacol. 1997 ; 25: 130-45 (Pubitemid 27220196)
15. Cook J. C., Klinefelter G. R., Hardisty J. F., Sharpe R. M., Foster P. M. Rodent Leydig cell tumorigenesis: A review of the physiology, pathology, mechanisms and relevance to humans. Crit Rev Toxicol. 1999 ; 29: 169-261 (Pubitemid 29169595)
16. Coulson M., Gibson G. G., Plant N., Hammond T., Graham M. Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: Implications for leydig cell carcinogenesis. Toxicol Appl Pharmacol. 2003 ; 192: 154-63 (Pubitemid 37203440)
17. Department of Health and Human Services, National Toxicology Program Database Search Application Web site: http://ntp-apps.niehs.nih.gov/ntp-tox/ index.cfm.
18. Dillberger J. E. Age-related pancreatic islet changes in Sprague-Dawley rats. Toxicol Pathol. 1994 ; 22: 48-55 (Pubitemid 24139628)
19. List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. Food and Drug Administration. 21 CFR Part 216 63. 1998 ;: 54082-89
20. Göggelmann W., Bauchinger M., Kulka U., Schmid E. Genotoxicity of 4-chloro-o-toluidine in Salmonella typhimurium, human lymphocytes and V79 cells. Mutat Res. 1996 ; 370: 39-47 (Pubitemid 26300946)
21. GoldL. S. (2008). Carcinogenic Potency Database. University of California-Berkeley Web site: http://potency.berkeley.edu/index.html.
22. Gopinath C. The predictive value of pathological findings in animal toxicity studies. J Toxicol Pathol. 1995 ; 8: 89-100
23. Greaves P. In Histopathology of Preclinical Toxicity Studies. New York: Elsevier Ltd. ; 2007: 818-19.
24. Hard G. C., Boorman G. A., Wolf D. C. Re-evaluation of the 2-year chloroform drinking water carcinogenicity bioassay in Osborne-Mendel rats supports chronic renal tubule injury as the mode of action underlying the renal tumor response. Toxicol Sci. 2000 ; 53: 237-44 (Pubitemid 30100140)
25. Harvey P. W. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: Prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol. 2005 ; 25: 179-83 (Pubitemid 40806337)
26. Hernandez L. G., van Steeg H., Luijten M., van Benthem J. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat Res. 2009 ; 682: 94-109
27. Holsapple M. P., Pitot H. C., Cohen S. H., Boobis A. R., Klaunig J. E., Pastoor T., Dellarco V. L., Dragan Y. P. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 2006 ; 89: 51-56 (Pubitemid 43013754)
28. Iatropoulos M. J. Pathologist's responsibility in the diagnosis of oncogenesis. Toxicol Pathol. 1983 ; 11: 132-42 (Pubitemid 14113110)
29. Ilnytsky Y., Koturbash I., Kovalchuk O. Radiation-induced bystander effects in vivo are epigenetically regulated in a tissue-specific manner. Environ Mol Mutagen. 2009 ; 50: 105-13
30. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. http://monographs.iarc.fr/ENG/ Monographs/PDFs/index.php
31. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Supplement 7: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42 (1987). http://monographs.iarc.fr/ENG/Monographs/PDFs/index.php.
32. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Volume 50: Pharmaceutical Drugs (1990). http://monographs.iarc.fr/ENG/Monographs/PDFs/index.php.
33. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Volume 96: Ethanol Consumption and Ethyl Carbamate (2010). http://monographs.iarc.fr/ENG/Monographs/PDFs/index. php.
34. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Volume 99: Some Aromatic Amines, Organic Dyes, and Related Exposures (2010). http://monographs.iarc.fr/ ENG/Monographs/PDFs/index.php.
35. ICH Guideline M3 (R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. 2009 ;:
36. ICH Guideline S1A: Need for Carcinogenicity Studies of Pharmaceuticals. 1995 ;:
37. ICH Guideline S1B: Testing for Carcinogenicity of Pharmaceuticals. 1997 ;:
38. ICH Guideline S1C: Dose Selection for Carcinogenicity Studies. 2008 ;:
39. ICH Guideline S2: Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. 2008 ;:
40. ICH Guideline S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. 1997 ;:
41. Ishmael J., Dugard P. H. A review of perchloroethylene and rat mononuclear cell leukemia. Regul Toxicol Pharmacol. 2006 ; 145: 178-84
42. Jack D., Poynter D., Spurling N. W. Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. Toxicology. 1983 ; 27: 315-20 (Pubitemid 13017985)
43. Jacobs A. Prediction for 2-year carcinogenicity study results for pharmaceutical products: How are we doing?. Toxicol Sci. 2005 ; 88: 18-23 (Pubitemid 41548743)
44. Jacobson-Kram D. Cancer risk assessment approaches at the FDA/CDER: is the era of the 2-year bioassay drawing to a close?. Toxicol Pathol. 2010a ; 38: 169-170
45. Jacobson-Kram D. A proposed vision on the future of carcinogenicity testing. Toxicologist. 2010b ; 114: 138
46. Jacobson-Kram D., Sistare F. D., Jacobs A. C. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol. 2004 ; 32(S1): 49-52 (Pubitemid 38437567)
47. Klaunig J. E., Babich M. A., Baetcke K. P., Cook J. C., Corton J. C., David R. M., DeLuca J. G., Lai D. Y., McKee R. H., Peters J. M., Roberts R. A., Fenner-Crisp P. A. PPAR agonist-induced rodent tumors: Modes of action and human relevance. Crit Rev Toxicol. 2003 ; 33: 655-780 (Pubitemid 38037444)
48. Koturbash I., Rugo R. E., Hendricks C. A., Loree J., Thibault B., Kutanzi K., Pogribny I., Yanch J. C., Engelward B. P., Kovalchuk O. Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo. Oncogene. 2006 ; 25: 4267-75 (Pubitemid 44100497)
49. Lee H. K., Kim Y.-H., Roh J. K. Clastogenicity of methapyrilene hydrochloride in cultured Chinese hamster cells. Mutat Res. 1994 ; 341: 77-82 (Pubitemid 24372987)
50. Long G. G., Cohen I. R., Gries C. L., Young J. K., Francis P. C., Capen C. C. Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicol Pathol. 2001 ; 29: 719-26 (Pubitemid 34032647)
51. McClain R. M. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol Pathol. 1989 ; 17: 294-306 (Pubitemid 19218939)
52. Melnick R. L., Kohn M. C., Poirier C. J. Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect. 1996 ; 104 (Suppl 1): 123-34 (Pubitemid 26123097)
53. Muehlbock O. Hormones in the genesis of cancer. Acta Un Int Cancr. 1959 ; 15: 62-66
54. Nagaoka T., Onodera H., Matsushima Y., Todate A., Shihutani. M., Ogasawara H., Maekawa A. Spontaneous uterine adenocarcinomas in aged rats and their relation to endocrine imbalance. J Cancer Res Clin Oncol. 1990 ; 116: 623-28 (Pubitemid 20386367)
55. National Cancer Institute (1979). Bioassay of 4-chloro-o-toluidine hydrochloride for possible carcinogenicity. http://ntp.niehs.nih.gov/ntp/htdocs/ LT-rpts/tr165.pdf. Technical Rpt Series No.165, DHEW Pub No. (NIH)79-1721.
56. Toxicology and carcinogenesis studies of tetrachloroethylene (perchloroethylene) in F344/N rats and B6C3F1 mice (inhalation studies). U.S. Department of Health and Human Services, Public Health Service. 1986 ;:
57. Research Triangle Park, NC: NTP ; 1990 :
58. Research Triangle Park, NC: NIEHS ; 1996 :
59. Neumann F. Early indicators for carcinogenesis in sex-hormone-sensitive organs. Mutat Res. 1991 ; 248: 341-56
60. Ohshima M., Ward J. M., Brennan L. M., Creasia D. A. A sequential study of methapyrilene hydrochloride-induced liver carcinogenesis in male F344 rats. J Natl Canc Inst. 1984 ; 72: 759-68 (Pubitemid 14169452)
61. Oosterhout J., Van Der Laan J., Waal E., Olejniczak K., Hilgenfeld M., Schmidt V., Bass R. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol. 1997 ; 25: 6-17 (Pubitemid 27117572)
62. No. 103: Detailed Review Paper on Transgenic Rodent Mutation Assays. Paris, France: OECD ; 2009 :
63. Prentice D. E., Meikle A. W. A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Hum Exper Toxicol. 1995 ; 14: 562-72
64. Pritchard J. B., French J. E., Davis B. J., Haseman J. K. The role of transgenic mouse models in carcinogen identification. Environ Health Perspect. 2003 ; 111: 444-54 (Pubitemid 36546520)
65. Reddy M. V., Sistare F. D., Christensen J. S., DeLuca J. G., Wollenberg G. K., DeGeorge J. J. An evaluation of chronic six- and twelve-month rat toxicology studies as predictors of two-year tumor outcome. Vet Pathol. 2010 ; 47: 614-29
66. Ross J., Barrowman J. A. Effect of experimental pancreatic growth on the content of xenobiotic-metabolizing enzymes in the pancreas. Gut. 1987 ; 28 (Suppl). 197-201
67. Snyder R. D. A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Mutat Res. 1998 ; 411: 235-48 (Pubitemid 28511386)
68. Storer R. D., Sistare F. D., Reddy M. V., DeGeorge J. J. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development. Toxicol Pathol. 2010 ; 38: 51-61
69. New York, NY: United Nations ; 2005 :
70. Ward J. M. Unique toxic lesions induced by chemical carcinogens in rodents: indications of a short-term bioassay for carcinogenesis testing of environmental chemicals. Med Hypotheses. 1980 ; 6: 421-25 (Pubitemid 10120735)
71. Weisburger E. K., Russfield A. B., Homburger F., Weisburger J. H., Boger E., Van Dongen C. G. Testing of twenty-one environmental aromatic amines or derivatives for long-term toxicity or carcinogenicity. J Environ Path Toxicol. 1978 ; 2: 325-56 (Pubitemid 9246952)
72. Wilson G. L., Longnecker D. S. In Endocrine and Hormonal Toxicology. New York: John Wiley & Sons ; 1999: 125-53.
73. World Health Organization, International Agency for Research on Cancer Web site: http://monographs.iarc.fr/.
74. Woutersen R. A., van Garderen-Hoetmer A., Lamers C. B. H. W., Scherer E. Early indicators of exocrine pancreas carcinogenesis produced by non-genotoxic agents. Mutat Res. 1991 ; 248: 291-302
75. Wysowski D. K., Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med. 2005 ; 165: 1363-69
76. Zwicker G. M., Eyster R. C. Chronic effect of corticosteroid oral treatment in rat on blood glucose and serum insulin levels, pancreatic islet morphology and immunostaining characteristics. Toxicol Pathol. 1993 ; 21: 502-8 (Pubitemid 24013218)